Lorraine Disipio, DO
Family Medicine · Darby, PANPI 1568561702
Payments from drug & device makers
Across 91 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$315
- AbbVie$177
- Boehringer Ingelheim$137
- Lilly USA, LLC$125
- Astellas Pharma US Inc$125
- GSK$103
- plus $589 from 20 others
What the payments were for
- Food & beverage$1,571100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 16 | $315 |
| AbbVie | 10 | $177 |
| Boehringer Ingelheim | 9 | $137 |
| Lilly USA, LLC | 6 | $125 |
| Astellas Pharma US Inc | 6 | $125 |
| GSK | 7 | $103 |
| Amarin Pharma, Inc. | 6 | $99 |
| Amgen | 6 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Merck | 3 | $39 |
| AstraZeneca | 3 | $38 |
| Abbott | 2 | $36 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $26 |
| Exact Sciences | 1 | $20 |
| Philips North America LLC | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Circassia Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Hologic Sales And Service, LLC | 1 | $13 |
How this compares
$1,571 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 85 | $95,074 |
| OzempicSemaglutide | 57 | $69,562 |
| JardianceEmpagliflozin | 44 | $58,944 |
| TrulicityDulaglutide | 31 | $44,784 |
| EliquisApixaban | 34 | $35,417 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $27,432 |
| MounjaroTirzepatide | 21 | $26,686 |
| FarxigaDapagliflozin Propanediol | 11 | $17,492 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $14,752 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $12,388 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $12,378 |
| VascepaIcosapent Ethyl | 19 | $11,600 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 37 | $7,173 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $7,047 |
| Rosuvastatin Calcium | 202 | $6,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia | $39 | $95,07485 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Stiolto Respimat, Tradjenta | $137 | $88,887101 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $125 | $71,46952 claims |
| Novo NordiskOzempic | $315 | $69,56257 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $103 | $46,93679 claims |
| PfizerEliquis | $15 | $35,41734 claims |
| AstraZenecaFarxiga | $38 | $17,49211 claims |
| AbbVieSynthroid | $177 | $4,70346 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Darby
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.